Timothy M. Schmidt

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · Journal of Clinical Oncology · 2021 · 255 citations

Medicine, Hematology, Pharmacotherapy +17

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Timothy M. Schmidt, Benjamin G. Barwick, Nisha S. Joseph et al. · Blood Cancer Journal · 2019 · 165 citations · Full text

Medicine, Hematology, Oncology +15

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · The Lancet Haematology · 2023 · 150 citations · Full text

Medicine, Internal Medicine, Oncology +12

HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial

Teri Liegler, Mohamed Abdel‐Mohsen, L. Gordon Bentley et al. · The Journal of Infectious Diseases · 2014 · 73 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

Saurabh Chhabra, Natalie S. Callander, Nicole Watts et al. · Transplantation and Cellular Therapy · 2022 · 59 citations · Full text

Medicine, Oncology, Pharmacotherapy +17